Shares of Acumen Pharmaceuticals Inc. were up 10% to $8.41 in premarket trading Monday after the company said regulators granted fast-track designation to its Alzheimer's disease treatment.
The U.S. Food and Drug Administration gave the designation to ACU193, a clinical-stage monoclonal antibody. Acumen is currently studying the drug in a Phase 1 trial examining safety and proof of mechanism.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.